Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer
University of Colorado Cancer CenterResults of ALTA-1 trial: Patients given brigatinib saw a statistically significant 51 percent reduction in the risk of progression or death compared with those given crizotinib.